Cytokeratin-19 positivity is acquired along cancer progression and does not predict cell origin in rat hepatocarcinogenesis

Oncotarget

Volumn 6, Issue 36, 2015, Pages 38749-38763

  Kowalik, Marta Anna ^a   Sulas, Pia ^a   Ledda Columbano, Giovanna Maria ^a   Giordano, Silvia ^b   Columbano, Amedeo ^a   Perra, Andrea ^a  

^a UNIVERSITY OF CAGLIARI   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

Author keywords

Cell origin; Hepatocarcinogenesis; Nrf2 Keap1; Oval cells; Preneoplastic foci

Indexed keywords

CASPASE 3; CYTOKERATIN 19; KELCH LIKE ECH ASSOCIATED PROTEIN 1; N (2 FLUORENYL)ACETAMIDE; TRANSCRIPTION FACTOR NRF2; TRANSCRIPTOME;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL; CELL DEDIFFERENTIATION; CELL EXPANSION; CELL PROLIFERATION; CELL TRANSFORMATION; CHOLINE METHIONINE DEFICIENT MODEL; CONTROLLED STUDY; EARLY PRENEOPLASTIC FOCUS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; LIVER CARCINOGENESIS; MALE; NONHUMAN; OVAL CELL; PHENOTYPE; PRECANCER; PRENEOPLASTIC HEPATOCYTE; RAT; RAT MODEL; RESISTANT HEPATOCYTE MODEL; STEM CELL; ANIMAL; BIOSYNTHESIS; CANCER STAGING; CARCINOGENESIS; DISEASE COURSE; EXPERIMENTAL LIVER NEOPLASM; FISCHER 344 RAT; GENETICS; METABOLISM; PATHOLOGY;

ANIMALS; CARCINOGENESIS; DISEASE PROGRESSION; KERATIN-19; LIVER NEOPLASMS, EXPERIMENTAL; MALE; NEOPLASM STAGING; PRECANCEROUS CONDITIONS; RATS; RATS, INBRED F344; TRANSCRIPTOME;

EID: 84948808123     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.5501     Document Type: Article

References (49)

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics. CA Cancer J Clin. 2014; 64:9-29.
2. Lee JS, Thorgeirsson SS. Genome-scale profiling of gene expression in hepatocellular carcinoma: classification, survival prediction, and identification of therapeutic targets. Gastroenterology. 2004; 127:S51-55.
3. Thorgeirsson SS, Grisham JW. Molecular pathogenesis of human hepatocellular carcinoma. Nat Genet. 2002; 31:339-346.
4. Farber E. The multistep nature of cancer development. Cancer Res. 1984; 44:4217-4223.
5. Bannasch P, Enzmann H, Klimek F, Weber E, Zerban H. Significance of sequential cellular changes inside and outside foci of altered hepatocytes during hepatocarcinogenesis. Toxicol Pathol. 1989; 17:617-628.
6. Sakamoto M, Hirohashi S, Shimosato Y. Early stages of multistep hepatocarcinogenesis - adenomatous hyperplasia and early hepatocellular carcinoma- Hum Pathol. 1991; 22:172-178.
7. Bralet MP, Pichard V, Ferry N. Demonstration of direct lineage between hepatocytes and hepatocellular carcinoma in diethylnitrosamine-treated rats. Hepatology. 2002; 36:623-630.
8. Durnez A, Verslype C, Nevens F, Fevery J, Aerts R, Pirenne J, Lesaffre E, Libbrecht L, Desmet V, Roskams T. The clinicopathological and prognostic relevance of cytokeratin 7 and 19 expression in hepatocellular carcinoma. A possible progenitor cell origin. Histopathology. 2006; 49:138-151.
9. Lee JS, Heo J, Libbrecht L, Chu IS, Kaposi-Novak P, Calvisi DF, Mikaelyan A, Roberts LR, Demetris AJ, Sun Z, Nevens F, Roskams T, Thorgeirsson SS. A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells. Nat Med. 2006; 12:410-416.
10. Libbrecht L, Desmet V, Van Damme B, Roskams T. The immunohistochemical phenotype of dysplastic foci in human liver: correlation with putative progenitor cells. J Hepatol. 2000; 33:76-84.
11. Libbrecht L, De Vos R, Cassiman D, Desmet V, Aerts R, Roskams T. Hepatic progenitor cells in hepatocellular adenomas. Am J Surg Pathol. 2001; 25:1388-1396.
12. Roskams T. Progenitor cell involvement in cirrhotic human liver diseases: from controversy to consensus. J Hepatol. 2003; 39:431-434.
13. Roskams TA, Libbrecht L, Desmet VJ. Progenitor cells in diseased human liver. Semin Liver Dis. 2003; 23:385-396.
14. Bernal SD, Stahel RA. Cytoskeleton-associated proteins: their role as cellular integrators in the neoplastic process. Crit Rev Oncol Hematol. 1985; 3:191-204.
15. Cooper D, Schermer A, Sun TT. Classification of human epithelia and their neoplasms using monoclonal antibodies to keratins: strategies, applications, and limitations. Lab Invest. 1985; 52:243-256.
16. Moll R, Franke WW, Schiller DL, Geiger B, Krepler R. The catalog of human cytokeratins: patterns of expression in normal epithelia, tumors and cultured cells. Cell. 1982; 31:11-24.
17. Strnad P, Stumptner C, Zatloukal K, Denk H. Intermediate filament cytoskeleton of the liver in health and disease. Histochem Cell Biol. 2008; 129:735-49.
18. Yang XR, Xu Y, Yu B, Zhou J, Qiu SJ, Shi GM, Zhang BH, Wu WZ, Shi YH, Wu B, Yang GH, Ji Y, Fan J. High expression levels of putative hepatic stem/progenitor cell biomarkers related to tumour angiogenesis and poor prognosis of hepatocellular carcinoma. Gut. 2010; 59:953-962.
19. Wu PC, Fang JW, Lau VK, Lai CL, Lo CK, Lau JY. Classification of hepatocellular carcinoma according to hepatocellular and biliary differentiation markers. Clinical and biological implications. Am J Pathol. 1996; 149:1167-75.
20. Ding SJ, Li Y, Tan YX, Jiang MR, Tian B, Liu YK, Shao XX, Ye SL, Wu JR, Zeng R, Wang HY, Tang ZY, Xia QC. From proteomic analysis to clinical significance: overexpression of cytokeratin 19 correlates with hepatocellular carcinoma metastasis. Mol Cell Proteomics. 2004; 3:73-81.
21. Uenishi T, Kubo S, Yamamoto T, Shuto T, Ogawa M, Tanaka H, Tanaka S, Kaneda K, Hirohashi K. Cytokeratin 19 expression in hepatocellular carcinoma predicts early postoperative recurrence. Cancer Sci. 2003; 94:851-857.
22. Tsuchiya K, Komuta M, Yasui Y, Tamaki N, Hosokawa T, Ueda K, Kuzuya T, Itakura J, Nakanishi H, Takahashi Y, Kurosaki M, Asahina Y, Enomoto N, et al. Expression of keratin 19 is related to high recurrence of hepatocellular carcinoma after radiofrequency ablation. Oncology. 2011; 80:278-288.
23. Kim H, Choi GH, Na DC, Ahn EY, Kim GI, Lee JE, Cho JY, Yoo JE, Choi JS, Park YN. Human hepatocellular carcinomas with "Stemness"-related marker expression: keratin 19 expression and a poor prognosis. Hepatology. 2011; 54:1707-1717.
24. Govaere O, Komuta M, Berkers J, Spee B, Janssen C, de Luca F, Katoonizadeh A, Wouters J, van Kempen LC, Durnez A, Verslype C, De Kock J, Rogiers V, et al. Keratin 19: a key role player in the invasion of human hepatocellular carcinomas. Gut. 2014; 63:674-685.
25. Fausto N, Campbell JS. The role of hepatocytes and oval cells in liver regeneration and repopulation. Mech Dev. 2003; 120:117-130.
26. Alison MR, Lovell MJ. Liver cancer: the role of stem cells. Cell Prolif. 2005; 38:407-421.
27. Solt DB, Medline A, Farber E. Rapid emergence of carcinogen-induced hyperplastic lesions in a new model for the sequential analysis of liver carcinogenesis. Am J Pathol. 1977; 88:595-618.
28. Golding M, Sarraf CE, Lalani EN, Anilkumar TV, Edwards RJ, Nagy P, Thorgeirsson SS, Alison MR. Oval cell differentiation into hepatocytes in the acetylaminofluorene-treated regenerating rat liver. Hepatology. 1995; 22:1243-1253.
29. Andersen JB, Loi R, Perra A, Factor VM, Ledda-Columbano GM, Columbano A, Thorgeirsson SS. Progenitor-derived hepatocellular carcinoma model in the rat. Hepatology. 2010; 51:1401-1409.
30. Petrelli A, Perra A, Cora D, Sulas P, Menegon S, Manca C, Migliore C, Kowalik MA, Ledda-Columbano GM, Giordano S, Columbano A. MicroRNA/gene profiling unveils early molecular changes and nuclear factor erythroid related factor 2 (NRF2) activation in a rat model recapitulating human hepatocellular carcinoma (HCC). Hepatology. 2014; 59:228-241.
31. Anilkumar TV, Golding M, Edwards RJ, Lalani EN, Sarraf CE, Alison MR. The resistant hepatocyte model of carcinogenesis in the rat: the apparent independent development of oval cell proliferation and early nodules. Carcinogenesis. 1995; 16:845-853.
32. Santos NP, Oliveira PA, Arantes-Rodrigues R, Faustino-Rocha AI, Colaço A, Lopes C, Gil da Costa RM. Cytokeratin 7/19 expression in N-diethylnitrosamine-induced mouse hepatocellular lesions: implications for histogenesis. Int J Exp Pathol. 2014; 95:191-198.
33. Shinozuka H, Lombardi B, Sell S. Iammarino RM Early histological and functional alterations of ethionine liver carcinogenesis in rats fed a choline-deficient diet. Cancer Res. 1978; 38:1092-1098.
34. Evarts RP, Nakatsukasa H, Marsden ER, Hsia CC, Dunsford HA, Thorgeirsson SS. Cellular and molecular changes in the early stages of chemical hepatocarcinogenesis in the rat. Cancer Res. 1990; 50:3439-3444.
35. Sell S, Dunsford HA. Evidence for the stem cell origin of hepatocellular carcinoma and cholangiocarcinoma. Am J Pathol. 1989; 134:1347-1363.
36. Sell S. Cellular origin of cancer: dedifferentiation or stem cell maturation arrest? Environ Health Perspect. 1993; 101:15-26.
37. De Lima VM, Oliveira CP, Alves VA, Chammas MC, Oliveira EP, Stefano JT, de Mello ES, Cerri GG, Carrilho FJ, Caldwell SH. A rodent model of NASH with cirrhosis, oval cell proliferation and hepatocellular carcinoma. J Hepatol. 2008; 49:1055-61.
38. Perra A, Kowalik MA, Ghiso E, Ledda-Columbano GM, Di Tommaso L, Angioni MM, Raschioni C, Testore E, Roncalli M, Giordano S, Columbano A. YAP activation is an early event and a potential therapeutic target in liver cancer development. J Hepatol. 2014; 61:1088-1096.
39. Frau C, Loi R, Petrelli A, Perra A, Menegon S, Kowalik MA, Pinna S, Leoni VP, Fornari F, Gramantieri L, Ledda-Columbano GM, Giordano S, Columbano A. Local hypothyroidism favors the progression of preneoplastic lesions to hepatocellular carcinoma in rats. Hepatology. 2015; 61:249-59.
40. Fuchs E, Weber K. Intermediate filaments: structure, dynamics, function, and disease. Annu Rev Biochem. 1994; 63:345-382.
41. Yimlamai D, Christodoulou C, Galli GG, Yanger K, Pepe-Mooney B, Gurung B, Shrestha K, Cahan P, Stanger BZ, Camargo FD. Hippo pathway activity influences liver cell fate. Cell. 2014; 157:1324-1338.
42. Enomoto K, Farber E. Kinetics of phenotypic maturation of remodeling of hyperplastic nodules during liver carcinogenesis. Cancer Res. 1982; 42:2330-2335.
43. Perra A, Kowalik MA, Pibiri M, Ledda-Columbano GM, Columbano A. Thyroid hormone receptor ligands induce regression of rat preneoplastic liver lesions causing their reversion to a differentiated phenotype. Hepatology. 2009; 49:1287-1296.
44. Roncalli M, Terracciano L, Di Tommaso L, David E, Colombo M. Gruppo Italiano Patologi Apparato Digerente (GIPAD); Società Italiana di Anatomia Patologica e Citopatologia Diagnostica/International Academy of Pathology Italian division (SIAPEC/IAP): Liver precancerous lesions and hepatocellular carcinoma: the histology report. Dig Liv Dis. 2011; 43S:S361-S372.
45. Kobayashi A, Kang MI, Okawa H, Ohtsuji M, Zenke Y, Chiba T, Igarashi K, Yamamoto M. Oxidative stress sensor Keap1 functions as an adaptor for Cul3-based E3 ligase to regulate proteasomal degradation of Nrf2. Mol Cell Biol. 2004; 24:7130-7139.
46. Sporn MB, Liby KT. NRF2 and cancer: the good, the bad and the importance of context. Nat Rev Cancer. 2012; 12:564-571.
47. Jaramillo MC, Zhang DD. The emerging role of the Nrf2-Keap1 signaling pathway in cancer. Genes Dev. 2013; 27:2179-2191.
48. Zavattari P, Perra A, Menegon S, Kowalik MA, Petrelli A, Angioni MM, Follenzi A, Quagliata L, Ledda-Columbano GM, Terracciano L, Giordano S, Columbano A. Nrf 2, but not ß-catenin, mutation represents an early event in rat hepatocarcinogenesis. Hepatology. 2015; 62:851-862.
49. Eckle VS, Buchmann A, Bursch W, Schulte-Hermann R, Schwarz M. Immunohistochemical detection of activated caspases in apoptotic hepatocytes in rat liver. Toxicol Pathol. 2004; 32:9-15.